Cargando…

Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy

Docetaxel is a well-known causative agent of nail alterations. The aim of this study was to reveal the impact of nail alterations associated with low-dose metronomic (LDM) docetaxel chemotherapy on the survival of non-small cell lung cancer (NSCLC) patients. Clinical information, survival data and n...

Descripción completa

Detalles Bibliográficos
Autores principales:	KIBATA, KAYOKO, TAMAKI, TAKESHI, INAGAKI, NORIKO, OGATA, MAKOTO, SHIMIZU, TOSHIKI, NOMURA, SHOSAKU
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629050/ https://www.ncbi.nlm.nih.gov/pubmed/23599750 http://dx.doi.org/10.3892/ol.2013.1178

Ejemplares similares

Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer
por: SHIMIZU, TOSHIKI, et al.
Publicado: (2013)

Primary intrahepatic malignant mesothelioma with multiple lymphadenopathies due to non-tuberculous mycobacteria: A case report and review of the literature
por: INAGAKI, NORIKO, et al.
Publicado: (2013)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
por: Nakaya, Aya, et al.
Publicado: (2018)

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
por: Niki, Maiko, et al.
Publicado: (2018)

Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation
por: Kurata, Takayasu, et al.
Publicado: (2017)

The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells
por: Kibata, Kayoko, et al.
Publicado: (2019)

Statins can suppress DC‐mediated Th2 responses through the repression of OX40‐ligand and CCL17 expression
por: Inagaki‐Katashiba, Noriko, et al.
Publicado: (2019)

Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report
por: Ogata, Makoto, et al.
Publicado: (2011)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer
por: Nakatani, Yuki, et al.
Publicado: (2017)

Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer
por: Nakaya, Aya, et al.
Publicado: (2017)

Can a rational design for metronomic chemotherapy dosing be devised?
por: Maraveyas, A, et al.
Publicado: (2005)

A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
por: Ishii, Nobuyasu, et al.
Publicado: (2021)

Metronomic Chemotherapy in Prostate Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2022)

Low‐dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma
por: Chen, Yu‐Pei, et al.
Publicado: (2022)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

Microparticles as Biomarkers of Blood Coagulation in Cancer
por: Nomura, Shosaku, et al.
Publicado: (2015)

Effect of triple therapy in patients with asthma-COPD overlap
por: Ishiura, Yoshihisa, et al.
Publicado: (2019)

Localized lymphadenopathy with myelodysplastic syndrome associated with tuberculosis
por: Nakaya, Aya, et al.
Publicado: (2019)

Efficacy of gefapixant, a P2X(3) antagonist, for lung cancer-related cough: a case report
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Efficacy of Gefapixant, a P2X(3) Antagonist, for Refractory Atopic Cough
por: Ishiura, Yoshihisa, et al.
Publicado: (2023)

Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas
por: Sheng Sow, Heng, et al.
Publicado: (2013)

Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O.G., et al.
Publicado: (2009)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

Metronomic palliative chemotherapy in maxillary sinus tumor
por: Patil, Vijay M., et al.
Publicado: (2016)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
por: Isono-Nakata, Rose, et al.
Publicado: (2018)

Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
por: Schito, Luana, et al.
Publicado: (2020)

Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
por: Koltai, Tomas, et al.
Publicado: (2019)

Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients
por: Nomura, Shosaku, et al.
Publicado: (2012)

Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap
por: Ishiura, Yoshihisa, et al.
Publicado: (2020)

Tiotropium Add-On and Treatable Traits in Asthma-COPD Overlap: A Real-World Pilot Study
por: Ishiura, Yoshihisa, et al.
Publicado: (2022)

Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing
por: Doi, Yusuke, et al.
Publicado: (2016)

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)

Use of metronomic chemotherapy in the management of a cat with abdominal haemangiosarcoma
por: Yee-Ka Cheng, Katrina, et al.
Publicado: (2018)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
por: Maharjan, Ruby, et al.
Publicado: (2019)

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman Andrés, et al.
Publicado: (2017)

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6de269c21nm6gbg1kgcrms87us